• Management of MRSA infection in the pediatric patient continues to rely on prompt diagnosis and localization of focus, and utilization of susceptibility data. • Drainage or debridement of abscess or necrotic material as well as knowledge of pharmacokinetic and pharmacodynamic data should guide appropriate therapy for specific infections. • Although vancomycin continues to be the cornerstone of therapy for MRSA infection in children, the increasing identification of strains having a vancomycin MIC at or beyond 1 mcg/mL may serve to change the scope of treatment for such infections in the future.
|Number of pages||11|
|Journal||Pediatrics in Review|
|State||Published - Dec 1 2011|